Insights

US market entry Flow Neuroscience has secured FDA approval for at-home tDCS and is actively expanding into the United States with a prescription-only model planned for 2026 and launched in 2026, presenting a clear sales opportunity for clinician-facing channels and payer discussions.

Clinical partnerships Past and ongoing collaborations with pharma players and clinical researchers indicate receptivity to joint trials and integration of Flow’s device into research and treatment protocols, suggesting opportunities for co-marketing, reimbursement discussions, and expanded clinical evidence sales.

RWE driven Extensive real-world evidence from tens of thousands of patients strengthens value propositions for payers and health systems, enabling a compelling case for coverage policy, outcome-based contracting, and health-economic analyses to drive adoption.

Small team leverage With a lean organization, Flow can benefit from scalable digital outreach, managed services, and partner ecosystems to accelerate market penetration in large, price-insensitive healthcare networks while maintaining agile customer support.

Global accessibility The at-home, first-line treatment design positions Flow as a convenient option for patients and clinics seeking accessible depression care, creating opportunities to upsell to adjunctive use, integration with existing care pathways, and multi-market expansion.

Similar companies to Flow Neuroscience

Flow Neuroscience Tech Stack

Flow Neuroscience uses 8 technology products and services including LinkedIn Ads, Hotjar, Amazon Web Services, and more. Explore Flow Neuroscience's tech stack below.

Media & News

Flow Neuroscience's Email Address Formats

Flow Neuroscience uses at least 2 email formats:
Flow Neuroscience Email FormatsExamplePercentage
First@flowneuroscience.comJohn@flowneuroscience.com
97%
First.Last@flowneuroscience.comJohn.Doe@flowneuroscience.com
3%

Frequently Asked Questions

What is Flow Neuroscience's official website and social media links?

Minus sign iconPlus sign icon
Flow Neuroscience's official website is flowneuroscience.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Flow Neuroscience generate?

Minus sign iconPlus sign icon
As of October 2026, Flow Neuroscience's annual revenue is estimated to be <$1M.

What is Flow Neuroscience's NAICS code?

Minus sign iconPlus sign icon
Flow Neuroscience's NAICS code is 62133 - Offices of Mental Health Practitioners (except Physicians).

How many employees does Flow Neuroscience have currently?

Minus sign iconPlus sign icon
As of October 2026, Flow Neuroscience has approximately 40 employees across 2 continents, including Europe and North America. Key team members include Chief Executive Officer And Founder: D. M., Cto & Co-Founder: E. M. R. and Chief Growth Officer: S. L. Explore Flow Neuroscience's employee directory with LeadIQ.

What industry does Flow Neuroscience belong to?

Minus sign iconPlus sign icon
Flow Neuroscience operates in the Mental Health Care industry.

What technology does Flow Neuroscience use?

Minus sign iconPlus sign icon
Flow Neuroscience's tech stack includes LinkedIn Ads, Hotjar, Amazon Web Services, HubSpot Content Hub, Cookiebot, Shopify, HubSpot and Heroku.

What is Flow Neuroscience's email format?

Minus sign iconPlus sign icon
Flow Neuroscience's email format typically follows the pattern of First@flowneuroscience.com. Find more Flow Neuroscience email formats with LeadIQ.

How much funding has Flow Neuroscience raised to date?

Minus sign iconPlus sign icon
As of October 2026, Flow Neuroscience has raised $13M in funding. The last funding round occurred on Aug 18, 2024.

When was Flow Neuroscience founded?

Minus sign iconPlus sign icon
Flow Neuroscience was founded in 2016.
Flow Neuroscience logo

Flow Neuroscience

Mental Health CareSweden11-50 Employees

Flow Neuroscience is a Sweden-based medical equipment manufacturer with 11-50 employees. It develops Flow, a brain stimulation headset paired with a therapy app intended for home use to treat Major Depressive Disorder in Europe and the United Kingdom, described as medically approved in those regions. The Flow device was launched in 2019 after a period of product development and regulatory approvals, and the company announced a brand refresh in 2022, including a new logo. In May 2022, Flow Neuroscience AB announced a clinical trial to assess the effectiveness of its at-home headset in reducing depressive symptoms, conducted with Curebase and Pharma Vends. Public reports mention venture financing activity in 2021, reflecting the company’s growth stage.

Section iconCompany Overview

NAICS Code
62133 - Offices of Mental Health Practitioners (except Physicians)
Founded
2016
Employees
11-50

Section iconFunding & Financials

  • $13M

    Flow Neuroscience has raised a total of $13M of funding over 7 rounds. Their latest funding round was raised on Aug 18, 2024 as a Convertible Note.

  • <$1M

    Flow Neuroscience's revenue is estimated to be in the range of <$1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.